These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
4. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts. Dannemann BR; Morris VA; Araujo FG; Remington JS J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453 [TBL] [Abstract][Full Text] [Related]
5. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Manning LS; Bowman RV; Darby SB; Robinson BW Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360 [TBL] [Abstract][Full Text] [Related]
6. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
7. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512 [TBL] [Abstract][Full Text] [Related]
8. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. Blottière HM; Zennadi R; Grégoire M; Aillet G; Denis MG; Meflah K; Le Pendu J Int J Cancer; 1993 Feb; 53(3):409-17. PubMed ID: 8428794 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nio Y; Zighelboim J; Berek JS; Bonavida B Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516 [TBL] [Abstract][Full Text] [Related]
11. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann GG; Zeuthen J; Claësson MH Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282 [TBL] [Abstract][Full Text] [Related]
12. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Komatsu F; Kajiwara M Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151 [TBL] [Abstract][Full Text] [Related]
13. [Human LAK cell induction and its biological characteristics]. Wu YY Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554 [TBL] [Abstract][Full Text] [Related]
14. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774 [TBL] [Abstract][Full Text] [Related]
16. Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. Clark DA; Hirte HW; Buick RN Br J Cancer; 1988 Oct; 58(4):415-8. PubMed ID: 3264715 [TBL] [Abstract][Full Text] [Related]